A Phase I Trial of the Aurora Kinase Inhibitor, ENMD-2076, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2016 Jul 14

PMID 27406088

Citations 18

Authors

Karen W L Yee

Hsiao-Wei T Chen

David W Hedley

Sue Chow

Joseph Brandwein

Andre C Schuh

Aaron D Schimmer

Vikas Gupta

Deborah Sanfelice

Tara Johnson

Lisa W Le

Jamie Arnott

Mark R Bray

Carolyn Sidor

Mark D Minden

Affiliations

Soon will be listed here.

Abstract

ENMD-2076 is a novel, orally-active molecule that inhibits Aurora A kinase, as well as c-Kit, FLT3 and VEGFR2. A phase I study was conducted to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D) and toxicities of ENMD-2076 in patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Patients received escalating doses of ENMD-2076 administered orally daily [225 mg (n = 7), 375 mg (n = 6), 325 mg (n = 9), or 275 mg (n = 5)]. Twenty-seven patients were treated (26 AML; 1 CMML-2). The most common non-hematological toxicities of any grade, regardless of association with drug, were fatigue, diarrhea, dysphonia, dyspnea, hypertension, constipation, and abdominal pain. Dose-limiting toxicities (DLTs) consisted of grade 3 fatigue, grade 3 typhilitis, grade 3 syncope and grade 3 QTc prolongation). Of the 16 evaluable patients, one patient achieved a complete remission with incomplete count recovery (CRi), three experienced a morphologic leukemia-free state (MLFS) with a major hematologic improvement in platelets (HI-P), and 5 other patients had a reduction in marrow blast percentage (i.e. 11-65 %). The RP2D in this patient population is 225 mg orally once daily.

Citing Articles

Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.

Marando L, Csizmar C, Patnaik M Haematologica. 2024; 110(1):22-36.

PMID: 39415698 PMC: 11694134. DOI: 10.3324/haematol.2024.286061.

Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA.

Chen M, Zhu H, Li J, Luo D, Zhang J, Liu W Ann Med. 2024; 56(1):2282184.

PMID: 38738386 PMC: 11095293. DOI: 10.1080/07853890.2023.2282184.

The two sides of chromosomal instability: drivers and brakes in cancer.

Hosea R, Hillary S, Naqvi S, Wu S, Kasim V Signal Transduct Target Ther. 2024; 9(1):75.

PMID: 38553459 PMC: 10980778. DOI: 10.1038/s41392-024-01767-7.

Small molecule agents for triple negative breast cancer: Current status and future prospects.

Ou Y, Wang M, Xu Q, Sun B, Jia Y Transl Oncol. 2024; 41:101893.

PMID: 38290250 PMC: 10840364. DOI: 10.1016/j.tranon.2024.101893.

Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.

Ivanov A, Alecsa M, Popescu R, Starcea M, Mocanu A, Rusu C Int J Mol Sci. 2023; 24(5).

PMID: 36902091 PMC: 10003692. DOI: 10.3390/ijms24054661.

References

Fletcher G, Brokx R, Denny T, Hembrough T, Plum S, Fogler W . ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2010; 10(1):126-37. DOI: 10.1158/1535-7163.MCT-10-0574. View

Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y . AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007; 110(6):2034-40. DOI: 10.1182/blood-2007-02-073700. View

Huang X, Luo S, Xu J, Li J, Xu D, Wang L . Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood. 2007; 111(5):2854-65. DOI: 10.1182/blood-2007-07-099325. View

Gautschi O, Heighway J, Mack P, Purnell P, Lara Jr P, Gandara D . Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008; 14(6):1639-48. DOI: 10.1158/1078-0432.CCR-07-2179. View

Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M . Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood. 2008; 112(7):2886-95. PMC: 2556624. DOI: 10.1182/blood-2008-01-128611. View

Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M . Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2003; 18(2):267-75. DOI: 10.1038/sj.leu.2403220. View

Moore A, Blagg J, Linardopoulos S, Pearson A . Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia. 2010; 24(4):671-8. DOI: 10.1038/leu.2010.15. View

Aguayo A, Kantarjian H, Estey E, Giles F, Verstovsek S, Manshouri T . Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002; 95(9):1923-30. DOI: 10.1002/cncr.10900. View

Grandage V, Gale R, Linch D, Khwaja A . PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005; 19(4):586-94. DOI: 10.1038/sj.leu.2403653. View

10.

Walsby E, Walsh V, Pepper C, Burnett A, Mills K . Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica. 2008; 93(5):662-9. DOI: 10.3324/haematol.12148. View

11.

Li J, Hong M, Chow J, Man W, Mak J, Ma H . Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe. Oncotarget. 2015; 6(11):9327-40. PMC: 4496220. DOI: 10.18632/oncotarget.3313. View

12.

How J, Yee K . ENMD-2076 for hematological malignancies. Expert Opin Investig Drugs. 2012; 21(5):717-32. DOI: 10.1517/13543784.2012.668882. View

13.

Zullo K, Guo Y, Cooke L, Jirau-Serrano X, Mangone M, Scotto L . Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma. Clin Cancer Res. 2015; 21(18):4097-109. PMC: 4581881. DOI: 10.1158/1078-0432.CCR-15-0033. View

14.

Rambaldi A, Wakamiya N, Vellenga E, Horiguchi J, Warren M, Kufe D . Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest. 1988; 81(4):1030-5. PMC: 329627. DOI: 10.1172/JCI113413. View

15.

Kottaridis P, Gale R, Frew M, Harrison G, Langabeer S, BELTON A . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the.... Blood. 2001; 98(6):1752-9. DOI: 10.1182/blood.v98.6.1752. View

16.

Goldberg S, Fenaux P, Craig M, Gyan E, Lister J, Kassis J . An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res Rep. 2014; 3(2):58-61. PMC: 4110881. DOI: 10.1016/j.lrr.2014.06.003. View

17.

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

18.

Cheson B, Bennett J, Kantarjian H, Pinto A, Schiffer C, Nimer S . Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96(12):3671-4. View

19.

Ye D, Garcia-Manero G, Kantarjian H, Xiao L, Vadhan-Raj S, Fernandez M . Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009; 2(1):2-8. PMC: 2713495. DOI: 10.1007/s12308-008-0019-3. View

20.

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S . Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001; 97(8):2434-9. DOI: 10.1182/blood.v97.8.2434. View